An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Positive
None.
Negative
None.
CHICAGO--(BUSINESS WIRE)--
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time. To access the presentation, please visit “Events” on the investor relations page of the Company’s website at www.xerispharma.com.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.
What is the latest announcement from Xeris Biopharma Holdings, Inc. (Nasdaq: XERS)?
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announced that their Chairman and CEO will present an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time.
When and where will the presentation take place?
The presentation will take place on Thursday, January 11, 2024, at 12:00 pm Pacific Time. To access the presentation, visit the 'Events' section on the investor relations page of Xeris Biopharma Holdings, Inc.'s website at www.xerispharma.com.
What is the goal of Xeris Biopharma Holdings, Inc. (Nasdaq: XERS)?
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies.
Who will be presenting at the conference?
Paul R. Edick, Xeris’ Chairman and CEO, will be presenting an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference.
Where can I access the presentation?
You can access the presentation on the 'Events' section of the investor relations page of Xeris Biopharma Holdings, Inc.'s website at www.xerispharma.com.
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
